A Study Comparing Anitocabtagen-Autoleucel with Standard Therapy in Participants with Relapsed/Refractory Multiple Myeloma
Résumé de l'étude
In this study, the investigational drug Anitocabtagen-Autoleucel (referred to as Anito-Cel) is compared with established standard therapies (chemo-immunotherapies) for the treatment of multiple myeloma. Participants will receive either Anito-Cel or the standard therapy. The treatment investigated in this study is made using so-called T-cells, a type of your own white blood cells. These cells are taken from the participants, modified to target cancer cells, and then re-administered to the participants. The treatment is administered once intravenously. We are investigating in this study whether the investigational drug Anito-Cel is effective and well-tolerated in the treatment of multiple myeloma. The study includes two treatment groups: the Anito-Cel group (investigational drug group) and the standard therapy group. The treatment in the Anito-Cel group involves the collection of white blood cells for the production of Anito-Cel, three days of chemotherapy as lymphodepletion to prepare for receiving Anito-Cel, and then a single infusion of Anito-Cel. For participants with rapidly progressing cancer, a bridging therapy may be administered during the production of Anito-Cel if necessary to keep the disease under control. This bridging therapy would consist of a short-term administration of one of the four standard therapies described below. The treatment in the standard therapy group includes the following four standard therapies, from which the investigator will select the most appropriate treatment: • Pomalidomide, Bortezomib, and Dexamethasone (PVd) • Daratumumab, Pomalidomide, Dexamethasone (DPd) • Carfilzomib, Daratumumab, Dexamethasone (KDd) • Carfilzomib and Dexamethasone (Kd) The probability of receiving Anito-Cel or the standard therapy is 50% for each.
(BASEC)
Intervention étudiée
The study includes two treatment groups: the Anito-Cel group (investigational drug group) and the standard therapy group.
The treatment in the Anito-Cel group involves the collection of white blood cells for the production of Anito-Cel, three days of chemotherapy as lymphodepletion to prepare for receiving Anito-Cel, and then a single infusion of Anito-Cel. For participants with rapidly progressing cancer, a bridging therapy may be administered during the production of Anito-Cel if necessary to keep the disease under control. This bridging therapy would consist of a short-term administration of one of the four standard therapies described below.
The treatment in the standard therapy group includes the following four standard therapies, from which the investigator will select the most appropriate treatment for you (the investigator will explain these treatments to you in detail):
• Pomalidomide, Bortezomib, and Dexamethasone (PVd)
• Daratumumab, Pomalidomide, Dexamethasone (DPd)
• Carfilzomib, Daratumumab, Dexamethasone (KDd)
• Carfilzomib and Dexamethasone (Kd)
(BASEC)
Maladie en cours d'investigation
relapsed/refractory multiple myeloma
(BASEC)
- Documented diagnosis of multiple myeloma (MM) in the medical history - 1 to 3 prior lines of anti-myeloma therapy - Documented evidence of progressive disease, based on the investigator's assessment at or within 12 months after the last dose of the last therapy - Measurable disease at the screening examination (BASEC)
Critères d'exclusion
- prior B-cell maturation antigen (BCMA)-targeted therapy - prior T-cell engager therapy - prior CAR-T therapy or other genetically modified T-cell therapy - Active or previous involvement of the central nervous system (CNS) or meninges in MM - Involvement of MM in the heart atrium or ventricle (BASEC)
Lieu de l’étude
Berne, Lausanne
(BASEC)
Sponsor
Gilead Sciences, Switzerléand
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Thomas Pabst
+41 (0) 31 632 41 14
thomas.pabst@clutterinsel.chInselspital, Onkologie
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Berne
(BASEC)
Date d'approbation du comité d'éthique
16.12.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible